• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Arena Pharmaceuticals appoints Kevin R. Lind as chief financial officer

Arena Pharmaceuticals appoints Kevin R. Lind as chief financial officer

June 20, 2016
CenterWatch Staff

Arena Pharmaceuticals has announced that Kevin R. Lind will join its management team as executive vice president and chief financial officer, effective June 15, 2016. Lind will report to Amit D. Munshi, Arena's president and chief executive officer.   

"Kevin is an accomplished executive with significant financial expertise and will be an exceptional addition to our team," said Munshi. "Kevin's broad finance experience in the healthcare environment will be an asset to us as we move toward implementing a streamlined, flexible cost structure and operating model, while enabling us to focus on our highest-potential value-driving opportunities."

Mr. Lind joins Arena with over 15 years of experience in healthcare banking and private equity. Prior to Arena, Lind was at TPG, most recently as a principal at TPG Special Situations Partners and initially atTPG-Axon's Pharma Partners group. Lind started his career in various capacities as a healthcare investment banker at Lehman Brothers. Lind received a B.S. from Stanford University in Biological Sciences and an M.B.A. from UCLA Anderson School of Management.

"It is a tremendous opportunity to join Arena at such an exciting time," said Lind. "I believe Arena's pipeline has great potential with its current phase II programs and I look forward to joining Arena's executive team to assist in delivering significant value to patients and shareholders."

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing